Real-world assessment of second-generation trabecular micro-bypass stents in open-angle glaucoma patients

IF 3.4

Advances in ophthalmology practice and research Pub Date : 2025-02-01 DOI:10.1016/j.aopr.2024.09.002

Vishal Vohra , Indira Madgula , Harshika Chawla

{"title":"Real-world assessment of second-generation trabecular micro-bypass stents in open-angle glaucoma patients","authors":"Vishal Vohra , Indira Madgula , Harshika Chawla","doi":"10.1016/j.aopr.2024.09.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>To assess the safety and efficacy of iStent inject placement in individuals with glaucoma with open angles in real world clinical settings.</div></div><div><h3>Methods</h3><div>A review was conducted on the medical records of individuals who received iStent inject implants starting from March 2018. The analysis focused on reductions in intraocular pressure (IOP) and glaucoma medication usage. Safety assessments encompassed intraoperative and postoperative issues, additional surgeries, and improvements in best-corrected visual acuity (BCVA).</div></div><div><h3>Results</h3><div>Analysis of 55 eyes of 48 patients that underwent iStent implantation revealed a mean age of 77 years (range: 51–97). The initial average intraocular pressure (IOP) in these eyes was 20.2 ± 6.4 mm Hg. Following surgery, IOP decreased by ≥ 20% compared to preoperative levels in 21 eyes (43.8%) over the 12-month follow-up period. Notably, there was a significant reduction in medication usage by the 12-month mark (<em>P</em> < 0.0042). Among the evaluated eyes, 9 exhibited a response to steroids, 3 had stents that were improperly positioned, 5 had stents that were over implanted, and 1 eye experienced an episode of iris prolapse.</div></div><div><h3>Conclusions</h3><div>The findings from the 12-month follow-up of iStent inject implants in standard clinical settings demonstrate a notable decrease in both intraocular pressure (IOP) and medication usage in eyes with concurrent open-angle glaucoma.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"5 1","pages":"Pages 16-21"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787460/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in ophthalmology practice and research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667376224000556","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

To assess the safety and efficacy of iStent inject placement in individuals with glaucoma with open angles in real world clinical settings.

Methods

A review was conducted on the medical records of individuals who received iStent inject implants starting from March 2018. The analysis focused on reductions in intraocular pressure (IOP) and glaucoma medication usage. Safety assessments encompassed intraoperative and postoperative issues, additional surgeries, and improvements in best-corrected visual acuity (BCVA).

Results

Analysis of 55 eyes of 48 patients that underwent iStent implantation revealed a mean age of 77 years (range: 51–97). The initial average intraocular pressure (IOP) in these eyes was 20.2 ± 6.4 mm Hg. Following surgery, IOP decreased by ≥ 20% compared to preoperative levels in 21 eyes (43.8%) over the 12-month follow-up period. Notably, there was a significant reduction in medication usage by the 12-month mark (P < 0.0042). Among the evaluated eyes, 9 exhibited a response to steroids, 3 had stents that were improperly positioned, 5 had stents that were over implanted, and 1 eye experienced an episode of iris prolapse.

Conclusions

The findings from the 12-month follow-up of iStent inject implants in standard clinical settings demonstrate a notable decrease in both intraocular pressure (IOP) and medication usage in eyes with concurrent open-angle glaucoma.

Abstract Image

查看原文本刊更多论文

第二代小梁微搭桥支架治疗开角型青光眼的临床评价。

背景：在现实世界的临床环境中，评估iStent注射置入治疗开角青光眼患者的安全性和有效性。方法：对2018年3月以来接受iStent注射种植体治疗的患者病历进行回顾性分析。分析的重点是眼压（IOP）和青光眼药物使用的降低。安全性评估包括术中和术后问题、额外手术和最佳矫正视力（BCVA）的改善。结果：48例55眼植入术患者，平均年龄77岁（51 ~ 97岁）。这些眼睛的初始平均眼压（IOP）为20.2±6.4 mm Hg。手术后，在12个月的随访期间，21只眼睛（43.8%）的IOP与术前水平相比下降了≥20%。值得注意的是，在12个月的时间里，药物使用显著减少(P结论：在标准临床环境下，iStent注射植入物12个月的随访结果表明，并发开角型青光眼的眼内压（IOP）和药物使用均显著降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊